$A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer$

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer

Background: We assessed the treatment effect of panitumumab plus best supportive care (BSC) vs BSC on overall survival (OS) in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) and report the first prospective extended RAS analysis in a phase 3 trial. Methods: P...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2016-11, Vol.115 (10), p.1206-1214
Hauptverfasser:	Kim, Tae Won, Elme, Anneli, Kusic, Zvonko, Park, Joon Oh, Udrea, Anghel Adrian, Kim, Sun Young, Ahn, Joong Bae, Valencia, Ricardo Villalobos, Krishnan, Srinivasan, Bilic, Ante, Manojlovic, Nebojsa, Dong, Jun, Guan, Xuesong, Lofton-Day, Catherine, Jung, A Scott, Vrdoljak, Eduard
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/51/1568 631/67/1504/1885 692/308/2779/109/1942 Adult Aged Aged, 80 and over Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - therapeutic use Biomarkers Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Chemotherapy clinical-study Colorectal cancer Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Combined Modality Therapy - methods Cross-Over Studies Drug Resistance Epidemiology Exons - genetics Female Humans Male Metastasis Middle Aged Molecular Medicine Mutation Mutation - genetics Oncology Patients Prospective Studies Proto-Oncogene Proteins p21(ras) - genetics ras Proteins - genetics Tumors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!